| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Alpha 1(I) Collagen (614-639), human targets the collagen fibrillar matrix assembly process. As a peptide fragment derived from type I collagen, it contains glycine-rich motifs that support triple-helix modeling. By interacting with collagen molecules, the peptide can inhibit the formation of collagen fibrils, making it a valuable tool for studying collagen assembly and structure. Type I collagen is the most abundant structural protein in connective tissues.
|
|---|---|
| ln Vitro |
In vitro, Alpha 1(I) Collagen (614-639), human functions as a peptide inhibitor of collagen fibrillar matrix assembly. It contains glycine-rich motifs that support triple-helix modeling. The peptide is used in biological research to study collagen structure, assembly, and interactions. Its effects on collagen fibrillogenesis can be assessed using turbidity assays, electron microscopy, or other biophysical methods.
|
| ln Vivo |
In vivo studies of Alpha 1(I) Collagen (614-639), human are limited, as it is primarily used as a research tool in in vitro assays. As a peptide inhibitor of collagen assembly, it could be used in animal models to study the role of collagen in tissue repair, fibrosis, and other conditions. However, its application is typically restricted to in vitro or ex vivo preparations. Further studies are needed to evaluate its in vivo effects and potential therapeutic applications.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, Alpha 1(I) Collagen (614-639), human is not typically used as an enzyme inhibitor or receptor ligand. Instead, it is used as a peptide for studying collagen assembly and structure. Its binding to collagen molecules and its effects on fibrillogenesis can be assessed using biophysical methods such as circular dichroism, turbidity assays, or electron microscopy. Standard assay conditions include physiological buffer systems with appropriate pH and ionic strength.
|
| Cell Assay |
For in vitro cellular experiments, Alpha 1(I) Collagen (614-639), human is tested in cell cultures to evaluate its effects on collagen deposition and matrix assembly. Cells that produce collagen, such as fibroblasts, are cultured in appropriate media and treated with various concentrations of the peptide. Collagen fibril formation and matrix organization are assessed using microscopy, immunohistochemistry, or biochemical assays. The peptide's effects on cell adhesion, migration, and proliferation can also be investigated.
|
| Animal Protocol |
For in vivo animal experiments, Alpha 1(I) Collagen (614-639), human can be administered to rodents via various routes, including subcutaneous injection or local application. The peptide's effects on tissue repair, fibrosis, or other collagen-related processes can be evaluated in appropriate animal models. Typical doses may range from microgram to milligram quantities. Tissue samples are collected for histological analysis of collagen deposition and matrix organization.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Alpha 1(I) Collagen (614-639), human are not relevant, as it is used as a research peptide rather than a therapeutic agent. As a peptide with a molecular weight of 2942.16, it would be expected to have low oral bioavailability and rapid clearance by proteases. When administered systemically, the peptide would likely be rapidly degraded. For in vitro studies, the peptide is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Alpha 1(I) Collagen (614-639), human are limited, as it is a research peptide. As a peptide fragment derived from a natural protein, it is generally considered to have low toxicity at the concentrations used for research. Standard toxicological assessments would include cytotoxicity screening in relevant cell lines. As with all research peptides, appropriate safety precautions should be taken when handling this compound.
|
| Additional Infomation |
Alpha 1(I) Collagen (614-639), human is a research peptide used to study collagen assembly and structure. No clinical trials or regulatory approvals have been reported for this peptide as a therapeutic agent. It is available from various peptide suppliers for research purposes only. The peptide is a fragment of alpha-1 type I collagen and is a peptide inhibitor of collagen fibrillar matrix assembly.
|
| CAS # |
210905-12-7
|
|---|---|
| PubChem CID |
171706646
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
41
|
| Hydrogen Bond Acceptor Count |
44
|
| Rotatable Bond Count |
91
|
| Heavy Atom Count |
210
|
| Complexity |
6880
|
| Defined Atom Stereocenter Count |
23
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
